Clinical Trials
82 trialsBGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
BeOne Medicines
ELEGANT
Stemline Therapeutics, Inc.
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
Novartis
CAMERAN
UNC Lineberger Comprehensive Cancer Center
SELECT
Yale University
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Hoffmann-La Roche
PIKALO-1
Eli Lilly and Company
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
ELEGANCE
Novartis
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
KANDELA-302
BeOne Medicines
PLUM
University of California, San Francisco
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc
TREAT ctDNA
European Organisation for Research and Treatment of Cancer - EORTC
EvoPAR-BR01
AstraZeneca
OPERA-02
Olema Pharmaceuticals, Inc.
Adjuvant WIDER
Novartis
OMAHA-015
Merck Sharp & Dohme LLC
CAMBRIA-1
AstraZeneca
POWER II
University of Virginia
I-SPY
QuantumLeap Healthcare Collaborative
ALEPRO
Universitaire Ziekenhuizen KU Leuven
IMPULSE
Novartis
INAVO123
Hoffmann-La Roche
AVZO-023-1001
Avenzo Therapeutics, Inc.
DEBRA
NRG Oncology
CHAMELEON
Memorial Sloan Kettering Cancer Center
Study of Letrozole in Recurrent Gliomas
University of Cincinnati
KAT6
Pfizer
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Hoosier Cancer Research Network
RaPhLRR
Hoosier Cancer Research Network
LaPemERLA
National Cancer Centre, Singapore
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
RAMP 301
Verastem, Inc.
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
Hebei Medical University Fourth Hospital
EndoMAP
Alliance Foundation Trials, LLC.
Morpheus-panBC
Hoffmann-La Roche
OPERA-01
Olema Pharmaceuticals, Inc.
FEMUS
Fudan University
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
University of Pittsburgh
BFR-ESS
Centre Leon Berard
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
University of Chicago
ALPINE: Maintenance Letrozole/Abemaciclib
Dana-Farber Cancer Institute
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
University of Washington
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
Fudan University